Drugs / SAR260301
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01673737 | Aug 2012 → Feb 2015 | cancer | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR260301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673737 ↗ |
| Action | Inhibit | “a potent PI3Kβ-selective inhibitor” PMID 28976556 ↗ Oct 2017 |
| Modality | Small molecule | — CHEMBL3112866 ↗ |
| Route | Oral | “Route of administration: oral” NCT01673737 ↗ |
| Target | PIK3CB | “a potent PI3Kβ-selective inhibitor” PMID 28976556 ↗ Oct 2017 |